

1. General information

Name: *Sebastian Bauer, Prof. Dr. med.*

DOB: *October 2nd, 1973*

City of birth: *Konstanz, Germany*

Work address: Innere Klinik (Tumorforschung)
Hufelandstraße 55
45147 Essen
Telefon +49 (0) 201 / 723 2112
Fax +49 (0) 201 / 723 5996
sebastian.bauer@uk-essen.de

Current position: Attending physician, Dept. of Medical Oncology
Chair Translational Oncology (personalized cancer therapy)
Head of Laboratory of Translational Sarcoma Research
Director Sarcoma Center (West German Cancer Center)

2. University training and degree

1993 - 1999 Julius-Maximilians-University Würzburg, Medical School, Approbation
1995 – 1999 MD Thesis, Cardiovascular Research Lab Prof. Ludwig Neyses, Dept. of Cardiology, Würzburg (Adenoviral transfection of neonatal cardiomyocytes)
1999 - 2003 Residency, Internal Medicine, University Hospital, Essen (Prof. Seeber)
2003 - 2005 Postdoctoral Fellowship (Mildred-Scheel-Stipend), Brigham and Women's Hospital, Dept. of Pathology, Harvard Medical School, Research Lab JA Fletcher, Boston, MA
2005 - 2009 Residency and Fellowship Medical Oncology; University Hospital Essen, Germany (Prof. M. Schuler); Degree in Internal Medicine and Hematology and Oncology

3. Advanced academic qualifications

2000 *Doctorate (MD Thesis; oral exam)*

2009 *Venia legendi (Habilitation; Internal Medicine) University of Duisburg-Essen, Germany*

4. Postgraduate professional career

2014 Chair of Translational Oncology (Personalized Cancer Therapy)

5. Other

- ESMO Faculty Member for Sarcoma (2015-); Track-Chair Sarcoma ESMO 2019, ESMO Scientific committee ESMO 2022
- ASCO Invited Speaker Sarcoma Track (2016-)
- AIO (Arbeitsgemeinschaft Internistische Onkologie/German Oncology Study Group) Chair: Steering Committee German Sarcoma Trial Working Group (2017-2019)

Member:

- European Organization for Research and Treatment of Cancer (EORTC)
- European Society of Medical Oncology (ESMO)
- American Association of Cancer Research (AACR)
- Deutsche Krebsgesellschaft (DKG)
- Arbeitsgemeinschaft Internistische Onkologie (AIO)
- Deutsches Konsortium für Translationale Krebsforschung (DKTK)

Reviewer:

„Acta Oncologica“
 “Annals of Oncology”
 „Annals of Surgical Oncology“
 „BBA reviews in Cancer“
 „Cancer, Chemotherapy, Pharmacology“
 “Cancer Discovery”
 „Clinical Cancer Research“
 “Clinical Sarcoma Research”
 „Clinical Pharmacokinetics“
 „Digestive and Liver Disease“
 „European Journal of Cancer“
 „European Journal of Hematology“
 „Gastroenterology“
 „Gut“
 „Journal of Clinical Investigation“
 “Journal of Clinical Oncology”
 „Journal of Clinical Pathology“
 „Journal of Pathology“
 „Laboratory Investigation“
 „Molecular Cancer“
 „Molecular Cancer Research“
 „Molecular Cancer Therapeutics“
 “Nature Medicine”
 „Nature Reviews Clinical Oncology“
 “Nature Reviews Disease Primer”
 “New England Journal of Medicine”
 „Oncogene“
 „PLOSone“
 „World Journal of Surgical Oncology“

Awards:

- | | |
|------|---|
| 2015 | Swiss GIST-Research-Award |
| 2009 | Award for Research and Innovation of the Deutsche Gesellschaft für Hämatologie und Onkologie |
| 2008 | „Young Master“-Award of the German Oncological Society (DGHO) |
| 2005 | “AACR Scholar-in-Training Award” for the abstract: „HSP90 inhibition by IPI-504 causes inhibition and degradation of KIT in imatinib-resistant GIST:a new point of attack for salvage therapy?“ |

2005	“Young Investigator Award”, Connective Tissue Oncology Society Annual Meeting – for the abstract „Targeting HSP90 in IM-resistant GIST: KIT degradation as a broadly relevant salvage strategy“
2005	“ASCO Foundation Merit Award”, American Society of Clinical Oncology for the abstract „KIT hyperactivation in imatinib-resistant GIST: Implications for salvage therapies“

Clinical Trial Experience (National coordinator Germany LKP):

INTRIGUE: A randomized phase III Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib (Global Co-Lead PI)

INVICTUS: Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies

VOYAGER: Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST.

POETIG: POnatinib After rEsisTance to Imatinib in GIST (POETIG) (Investigator-initiated trial)

WTZ-GIST-09-01: Phase I study of LBH589 in combination with imatinib in imatinib- and sunitinib-refractory GIST (Investigator-initiated trial)

BLU-285-1101 Eine Phase-1-Studie zur Untersuchung von BLU-285 bei Patienten mit gastrointestинаl Stroma-Tumoren (GIST) und anderen rezidivierten und refraktären soliden Tumoren.

CHDM201X2103c: Eine offene, multizentrische Phase Ib/II Studie mit oral verabreichtem HDM201 in Kombination mit oral verabreichtem LEE011 bei adulten Liposarkom-Patienten.

cHDM2012103: Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt

PLX108-10 ENLIVEN Doppelblinde, randomisierte, placebokontrollierte Phase-III-Studie zu oral verabreichtem PLX3397 bei Probanden mit pigmentierter villonodulärer Synovialitis oder tenosynovialem Riesenzelltumor (LKP Deutschland)

BMS CA224-020 A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors (LKP Deutschland)

SAKK 56 First-line therapy of metastatic GIST with dasatinib

EORTC 62024: Intermediate and high risk localized, completely resected,gastrointestinal stromal tumors (GIST) expressing KIT receptor: a controlled randomized trial on adjuvant imatinib mesylate (Glivec) versus no further therapy after complete surgery

CGM097 A Phase I, open-label, multi-center, dose escalation study of oral CGM097, a p53/HDM2-interaction inhibitor, in adult patients with selected advanced solid tumors.

CMEK162X2203 A phase Ib/II, open-label, multicenter study of AEB071 (PKC-inhibitor) and MEK162 (MEK-inhibitor) in adult patients with metastatic uveal melanoma.

TRC112765 Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag

I5B-MC-JGDR Phase-Ib-Studie zu Olaratumab, Doxorubicin und Ifosfamid beim fortgeschrittenen oder Weichteilsarkom

“Phase I study of adjuvant immunization with MAGE peptides in patients with resected stage I or stage II non-small cell lung cancer”

Local PI for clinical trials

EPAZ: A Trial Comparing Two Medications as First Treatment in Elderly Patients With Metastatic or Advanced Soft Tissue Sarcoma

MEDISARC: Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma

NCT03110744: CDK4/6 Inhibition in Locally Advanced/Metastatic Chordoma

SSGXXII Randomized Phase III testing imatinib for 3 or 5 years in high risk GIST

EVA (GISG-06) EVA (evaluation of votrient in angiosarcoma): einarmige, multizentrische offene Phase-II-Studie zur Überprüfung der Wirksamkeit der Kombination von Paclitaxel mit Pazopanib bei fortgeschrittenen und rezidivierten Angiosarkomen

PAGIST Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib

AEGIS Open Label, Dose Escalation Trial of Oral Eg5 Kinesin-spindle Inhibitor 4SC-205 in Patients With Advanced Malignancies

EPAZ “A randomized phase II trial comparing pazopanib with doxorubicin as first line treatment in elderly patients with metastatic or advanced soft tissue sarcoma”

E7389-G000-309 „A randomized, open-label, multicenter, phase III study to compare the efficacy and safety of ericulin with dacarbazine in subjects with soft tissue sarcomas“.

DOVIGIST Phase II trial to evaluate the efficacy and safety of Dovitinib (TKI258) in patients with gastrointestinal stromal tumors refractory and/or intolerant to imatinib

A Study of **IMC-3G3** in Previously Treated Patients With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors

CSTI571BDE78T “Prospective, explorative trial for the detection of circulating cellfree tumor DNA in the plasma of patients with gastrointestinal stromal tumors (GIST) harboring activating mutations of CKIT or PDGFRA pre/post surgery or pre/under treatment with a tyrosine kinase inhibitor or progressive disease irrespective of current or planned treatment”

CAMN107G2301 “A randomised, open label, multi-center phase III study to evaluate the efficacy and safety of nilotinib in adult patients with unresectable or metastatic GIST

CAMN107DDE05 “An open-label, multi-center study to evaluate the efficacy of nilotinib in adult patients with gastrointestinal stromal tumors resistant to imatinib and sunitinib”

AP23573-07-302 “A pivotal trial to determine the efficacy and safety of AP23573 when administered as maintenance therapy to patients with metastatic soft-tissue or bone sarcomas “

Desmoid 394-10 “Phase II study to evaluate Glivec (Imatinib Mesylate) to induce progression arrest in aggressive fibromatosis / desmoids tumors not amenable to surgical resection with R0 intent or accompanied by unacceptable function loss.”

ET-C-002-07: “A Randomized, Multicenter, Phase III Trial of Trabectedin (Yondelis®) versus Doxorubicin-based Chemotherapy as First-Line Therapy in Patients with Translocation-Related Sarcomas (TRS)

EWING 2008: “Treatment optimization trial in primary and metastatic Ewing Sarcoma Family Tumors”

CSTI571JDE74: „An open-label, multicenter, expanded access study of imatinib mesylate in adult patients with GIST in adjuvant setting after R0-resection”

EORTC62072: „A randomized double blind phase III trial of Pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or following prior therapy“

CAMN107A2201: „A randomized, open-label, multi center study to evaluate the efficacy of nilotinib versus best supportive care with or without a tyrosine kinase inhibitor (investigator's choice) in adult patients with gastrointestinal stromal tumors resistant to both imatinib and sunitinib“

CRAD001C2454: „Multicenter, single-arm, two-stage phase II trial of RAD001 (everolimus) with Glivec® in Glivec®-resistant patients with progressive GIST“

SSG XVIII: „Short (12 months) versus long (36 months) duration of adjuvant treatment with the tyrosinekinase inhibitor imatinib mesylate of operableGIST with a high risk for recurrence“

IPI-504-06: „A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Evaluating the Efficacy and Safety of IPI-504 in Patients with Metastatic and/or Unresectable Gastrointestinal Stromal Tumors Following Failure of at Least Imatinib and Sunitinib“

EORTC62012: „Randomised trial of single agent doxorubicin versus doxorubicin plus ifosfamide in the first line treatment of advanced or metastatic soft tissue sarcoma“

EORTC62051: „Phase II study of E7389 administered as an IV infusion day 1 and 8 every 3 weeks in pretreated patients with advanced and/or metastatic soft tissue sarcomas“

AIO-Studie: „Randomisierte Phase II-Studie von Trofosfamid versus Adriamycin bei älteren Patienten mit unvorbehandeltem metastasiertem Weichteilsarkom“

AIO-Studie: „Phase II Studie zu Pemetrexed bei vorbehandelteten Weichteilsarkomen“

EORTC 62061: “Randomized phase II study of brostallicin versus doxorubicin as first line chemotherapy in patients with advanced or metastatic soft tissue sarcoma”

EORTC-62006: „Exatecan as second-line treatment in advanced soft tissue sarcoma“

EORTC-62961: „Randomized study comparing neoadjuvant chemotherapy +/- regional hyperthermia in the treatment of high-risk soft tissuesarcomas in adults“

EORTC-62931: „Randomized trial of adjuvant chemotherapy with high-dose doxorubicin, ifosfamide and lenograstim in high grade soft tissue sarcoma“

EORTC-62981: „Euro-Ewing (European Ewingtumour working initiative of national groups) 99 study“

CSTI571BDE08: „Open-label phase III trial with STI571 in patients with inoperable or metastasized gastrointestinal stromal tumors with expression of CD117“

ND029902 S: „A phase II study with MEN 10755 in patients with advanced or metastatic soft tissue sarcoma (MAC-01) “

Publications

ORCID ID: <https://orcid.org/0000-0001-5949-8120>

Publons profile: <https://publons.com/researcher/2735165/sebastian-bauer/metrics/>

Research Gate: https://www.researchgate.net/profile/Sebastian_Bauer4/scores

H-Index: 36 (Publons)

Year	Authors	Title	Journal	IF
2021	Kang YK, George S, Jones RL, Rutkowski P, ..., Heinrich M, Bauer S	Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor: A Randomized, Open-label Phase III Study	Journal of Clinical Oncology, in press	33
2021	Bauer S, Demetri GD, Halilovic E, Dummer R, Meille C, Tan DSW, Guerreiro N, Jullion A, Ferretti S, Jeay S, van Bree L, Hourcade-Potelleret F, Wuerthner JU, Fabre C, Cassier PA	Pharmacokinetic-pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies	Br J Cancer 2021 Jun 17. doi: 10.1038/s41416-021-01444-4	5,8
2021	Horak P, Heining C, Kreutzfeldt S, Hutter B, Mock A, Hullein J, ..., Bauer S, ..., Fröhling S	Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers	Cancer Discov 2021 Jun 10; candisc.0126.20 21.	29
2021	Stacchiotti S, Miah AB, Frezza AM, Messiou C, Morosi C, Caraceni, Antonescu CR, Bajpai J, Baldini E, Bauer S, ..., Gronchi A	Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts	ESMO Open . 2021 Jun 2;6(3):100170.	5,3
2021	Jansen P, Müller HG; Lodde G, Zaremba A, Möllger I, Sucker A, Paschen A, Esser S, Schaller J, Gunzer M, Standl F, Bauer S, Schadendorf D, Mentzel T, Hadachik E, Griewank KG	GNA14, GNA11, and GNAQ Mutations Are Frequent in Benign but Not Malignant Cutaneous Vascular Tumors	Front Genet . 2021 Apr 30;12:663272	3,8
2021	Collaud S, Stork T, Dirksen U, Pöttgen C, Hegedüs B, Schildhaus HU, Bauer S; Aigner C	Surgical Treatment for Primary Chest Wall Sarcoma: A Single-Institution Study	J Surg Res . 2021 Apr;260:149-154	2,2
2021	Stork T, Boemans R, Hardes J, Streitbürger A, Dirksen U, Pöttgen C, Schildhaus HU, Bauer S, Collaud S, Aigner C	Number of metastases and their response to chemotherapy impact survival of patients with isolated lung metastases from bone-derived sarcoma	BMC Cancer . 2021 Apr 7;21(1):375	3,2
2021	Pink D, Andreou D, Bauer S, Brodowicz T, Kasper B, Reichardt P, Richter S, Lindner LH, Szkandera J, Gründwald V, Kebenko M, Kirchner M, Hohenberger P	Treatment of Angiosarcoma with Pazopanib and Paclitaxel: Results of the EVA (Evaluation of Votrient® in Angiosarcoma) Phase II Trial of the German Interdisciplinary Sarcoma Group (GISG-06)	Cancers (Basel) . 2021 Mar 11;13(6):1223	6,1
2021	Starzer AM, Berghoff AS, Hamacher R, Tomasich E, Feldmann K, Hatzioannou T, Traint S, Lamm W, Noeauer-Huhmann IM, Furtner J, Müllauer L, Amann G, Bauer S, Schildhaus HU, Preusser M, Heller G, Brodowicz T	Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients	J Immunother Cancer . 2021 Mar 9(3):e001458.	10,3
2021	Schaefer IM, Lundberg MZ, Demicco EG, Przybyl J, Matusiak M, Chibon F, Ingram DR, Hornick JL, Wang WL, Bauer S; Baker LH, Lazar AJ, van de Rijn M, Marino-Enriquez A, Fletcher JA	Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomas	Cancer . 2021 Mar 31. doi: 10.1002/cncr.33542	5,7

2021	Zöllner SK, Amatruada J, Bauer S, Collaud S; de Alava E, DuBOis SG, Hardes J, Hartmann W, Kovar H, Metzler M, Shulman DS, Sreitbürger A, Timmermann B, Toretsky JA, Uhlenbruch Y, Vieth V, Grunewald TGP, Dirksen U	Ewing Sarcoma-Diagnosis, Treatment, Clinical Challenges and Future Perspectives	J Clin Med . 2021 Apr 14;10(8):1685	1,9
2021	Dieckmann N, Schildhaus HU, Bauer S	Tropomyosin receptor kinases in sarcomas - of joy and despair	Curr Opin Oncol . 2021 Jul 1;33(4):336-344.	3,3
2021	Kessler L, Ferdinandus J, Hirmas N, Bauer S, Dirksen U, Zarrad F, Nader M, Chodyla MK, Milosevic A, Umutlu L, Schuler M, Podleska LE; Schildhaus HU, Fendler WP, Hamacher R	Ga-68-FAPI as diagnostic tool in sarcoma: Data from the FAPI-PET prospective observational trial	J Nucl Med . 2021 Apr 30;jnumed.121.262096	7,8
2021	Berenthal NM, Spierenburg G, Healey JH, Palmerini E, Bauer S, Gelderblom H, Staals EL, Lopez-Bastida J, Fronk EM, Ye X, Laeis P, van de Sande MAJ	The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective multicenter study	Orphanet J Rare Dis . 2021 Apr 29;16(1):191.	3,5
2021	Jones RL, Serrano C, von Mehren M, George S, Heinrich MC, Kang YK, Schöffski P, Cassier PA, Mir O, Chawla SP, Eskens FALM, Rutkowski P, Tap WD, Zhou T, Roche M, Bauer S.	Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial.	Eur J Cancer. 2021 Jan 15;145:132-142	6,7
2021	George S, Jones RL, Bauer S, Kang YK, Schöffski P, Eskens F, Mir O, Cassier PA, Serrano C, Tap WD, Trent J, Rutkowski P, Patel S, Chawla SP, Meiri E, Gordon M, Zhou T, Roche M, Heinrich MC, von Mehren M.	Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least 3 Prior Lines of Therapy.	Oncologist. 2021 Jan 16, online ahead of print	5,0
2020	Ludwig J, Haubold J, Heusner TA, Bauer S, Siveke JT, Richly H, Wetter A, Umutlu L, Theysohn JM.	Lactate Dehydrogenase Prior to Transarterial Hepatic Chemoperfusion Predicts Survival and Time to Progression in Patients with Uveal Melanoma Liver Metastases	Rofo. 2020 Dec 21	1,8
2020	Joseph CP, Abaricia SN, Angelis MA, Polson K, Jones RL, Kang YK, Riedel RF, Schöffski P, Serrano C, Trent J, Tetzlaff ED, Si TD, Zhou T, Doyle A, Bauer S, Roche M, Havnaer T	Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors.	Oncologist. 2020 Dec 10, online ahead of print	5
2020	Albrecht M, Hadaschik E, Zimmer L, Livingstone E, Hamacher R, Bauer S, Schadendorf D, Ugurel S	[Cutaneous angiosarcoma clinically presenting as Quincke's edema	Hautarzt. 2021 Jan 13	1
2020	Lewis JH, Gelderblom H, van de Sande M, Stacchiotti S, Healey JH, Tap WD, Wagner A, Lopez Pusa A, Druta M, Lin Chia-Chi, Baba HA, Choi Youngsook, Wang Q, Shuster DE, Bauer S	Pexidartinib long-term hepatic safety profile in TGCT patients	Oncologist. 2020 Dec 8, online ahead of print	5
2020	Evaluation of 18F-FDG PET and DWI datasets for the prediction of therapy response of soft tissues sarcomas under neoadjuvant isolated limb perfusion. Chodyla M, et al. Among authors: bauer s.	Chodyla M, Demircioglu A, Schaarschmidt B, Bertram S, Bruckmann NM, Haferkamp J, Li Y, Bauer S, Podleska L, Rischpler C, Forsting M, Herrmann K, Umutlu L, Grueneisen J.	J Nucl Med. 2020. PMID: 32737246	8
2020	Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up.	Joensuu H, Eriksson M, Sundby Hall K, Reichardt A, Hermes B, Schütte J, Cameron S, Hohenberger P, Jost PJ, Al-Batran SE, Lindner LH, Bauer S; Wardelmann E, Nilsson B, Kallio R, Jaakkola P, Junnila J, Alvegard T, Reichardt P	JAMA Oncol. 2020 online first	25
2020	Targeting Her2-insYVMA with Covalent Inhibitors-A Focused Compound	Lategahn J, Hardick, J, Grabe T, Niggenaber J, Jeyakumar K, Keul M, Tumbrink HL, Becker C,	J Med Chem. 2020. PMID: 32931277	6

	Screening and Structure-Based Design Approach. Lategahn J, et al. Among authors: bauer s. <i>J Med Chem.</i> 2020. PMID: 32931277	Hodson L, Kirschner T, Klöveborn P, Ketzer J, Baumann M, Terheyden S, Unger A, Weisner J, Müller M, van Otterlo WAL, Bauer S , Rauh D		
2020	Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study	Grünwald V, Karch A, Schuler M, Schöffski P, Kopp HG, Bauer S; Kasper B, Lindner LH, Chemnitz JM, Crysandt M, Stein A, Steffen B; Richter S, Egerer G, Ivanyi P, Zimmermann S, Lio Xiaofei, Kunitz A	<i>J Clin Oncol</i> 2020 Oct 20;38(30):3555-3564	33
2020	Grunewald S, Klug L, Mühlberg T, Lategahn J, Falkenhorst J, Town A, Ehrt C, Wardelmann E, Hartmann W, Schildhaus HU, Treckmann J, Fletcher JA, Jung S, Czodrowski P, Miller S; Schmidt-Kittler O, Rauh D; Heinrich MC*, Bauer S*†.	Mechanisms of avapritinib resistance in PDGFRA-mutant GIST	Cancer Discovery, online first	28
2020	Blay JY, Serrano C, Heinrich M, Zalcberg J, Bauer S , Gelderblom H, Schöffski P, Jones RL, Attia S, D'Amato G, Chi P, Reichardt P, Meade J, Shi K, Ruiz-Soto R, George S, von Mehren M	Ripretinib in patients with advanced gastrointestinal stromal tumor (GIST): a randomized, double-blind, placebo-controlled phase 3 study (INVICTUS)	<i>Lancet Oncology</i> , online first	35
2020	Heinrich M, Jones RL, von Mehren M, Schöffski P, Serrano C, Kang YK, Cassier PA, Mir O, Eskens F, Tap WD, Rutkowsk P, Chawla SP, Trent J, Tugnait M, Evans EK, Lauz T, Zhou T, Roche M, Wolf BB, Bauer S* , George S* (*shared senior)	Avapritinib, a selective PDGFRA D842V inhibitor for gastrointestinal stromal tumor (GIST)	<i>Lancet Oncology</i> , online first	35
2020	Collaud S, Stork T, Schildhaus HU, Pöttgen C, Plönies T, Valdivia D, Zaatar M, Dirksen U, Bauer S, Aigner C.	Multimodality treatment including surgery for primary pulmonary sarcoma: Size does matter.	<i>J Surg Oncol.</i> 2020 May 14. doi: 10.1002/jso.25979. [Epub ahead of print]	3,2
2020	Scheer M, Blank B, Bauer S , Vokuhl C, Stegmaier S, Feuchtgruber S, Henssen A, Sparber-Sauer M, Eggert A, Handgretinger R, Pekrun A, Rossig C, Rutkowski S, Schlegel PG, Schrappe M, Simon T, Kazanowska B, Niggli F, Ladenstein R, Ljungman G, Jahnukainen K, Fuchs J, Bielack SS, Koscielniak E, Klingebiel T	Synovial sarcoma disease characteristics and primary tumor sites differ between patient age groups: a report of the Cooperative Weichteilsarkom Studiengruppe (CWS).	<i>J Cancer Res Clin Oncol.</i> 2020 Apr;146(4):953-960	3,3
2020	Agaimy A, Skalova A, Franchi A, Alshagroud R, Gill AJ, Stoehr R, Baumhoer D, Bauer S.	Ameloblastic fibrosarcoma: clinicopathological and molecular analysis of seven cases highlighting frequent BRAF and occasional NRAS mutations.	<i>Histopathology.</i> 2020 May;76(6):814-821	3,4
2020	Andreou D, Ranft A, Gosheger G, Timmermann B, Ladenstein R, Hartmann W, Bauer S , Baumhoer D, van den Berg H, Dijkstra PDS, Dürr HR, Gelderblom H, Hardes J, Hjorth L, Kreyer J, Kruseova J, Leithner A, Scobioala S, Streitbürger A, Tunn PU, Wardelmann E, Windhager R, Jürgens H, Dirksen U	Which Factors Are Associated with Local Control and Survival of Patients with Localized Pelvic Ewing's Sarcoma? A Retrospective Analysis of Data from the Euro-EWING99 Trial.	<i>Clin Orthop Relat Res.</i> 2020 Feb;478(2):290-302	4,1
2019	J.T. Hartmann, H.G. Kopp, V. Gruenwald, S. Piperno-Neumann, A. Kunitz, R. Hofheinz, L. Mueller, M. Geissler, M. Horger, P. Fix, J. Chemnitz, M. Neise, T. Wehler, I. Zander, R. Eckert, C. Hann von Weyhern, S. Bauer , F. Mayer	Randomized Phase II Trial of Trofosfamide vs. Doxorubicin in Elderly Patients with untreated metastatic Soft Tissue Sarcoma	<i>Eur J Cancer.</i> 2020 Jan;124:152-160 (epub ahead 2019)	6,7
2019	Mühlberg T, Ketzer J, Heinrich MC, Grunewald S, Marino-Enriquez A,	KIT-Dependent and KIT-Independent Genomic	<i>Mol Cancer Ther.</i> 2019	4,9

	Trautmann M, Hartmann W, Wardelmann E, Treckmann J, Worm K, Bertram S, Herold T, Schildhaus HU, Glimm H, Stenzinger A, Brors B, Horak P, Hohenberger P, Fröhling S, Fletcher JA, Bauer S .	Heterogeneity of Resistance in Gastrointestinal Stromal Tumors – TORC1/2 Inhibition as Salvage Strategy.	Nov;18(11):1985-1996	
2019	Grueneisen J, Schaarschmidt B, Demircioglu A, Chodyla M, Martin O, Bertram S, Wetter A, Bauer S , Fendler WP, Podleska L, Forsting M, Herrmann K, Umutlu L.	18F-FDG PET/MRI for Therapy Response Assessment of Isolated Limb Perfusion in Patients with Soft-Tissue Sarcomas.	J Nucl Med. 2019 Nov;60(11):1537-1542	7,4
2019	Lategahn J, Keul M, Kloekorn P, Tumbrink H, Niggenaber J, Muller M, Hodson L, Fläschhoff M, Hardick J, Grabe T, Engel J, Schultz-Fademrecht C, Baumann M, Ketzer J, Muhlenberg T, Hiller W, Gunther G, Unger A, Muller H, Heimsoeth A, Golz C, Blank-Landeshammer B, Kollipara L, Zahedi RP, Strohmann C, Hengstler JG, van Otterlo WAL, Bauer S and Daniel Rauh	Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S	Chemical Science 2019 Oct DOI: 10.1039/c9sc03445e	9,6
2019	Jilg S, Rassner M, Maier J, Waldeck S, Kehl V, Follo M, Philipp U, Sauter A, Specht K, Mitschke J, Lange T, Bauer S , Jost PJ, Peschel C, Duyster J, Gaiser T, Hohenberger P, von Bubnoff N.	Circulating cKIT and PDGFRA DNA indicates disease activity in Gastrointestinal Stromal Tumor (GIST).	Int J Cancer. 2019 Oct 15;145(8):2292-2303	5,0
2019	Andreou D, Ranft A, Gosheger G, Timmermann B, Ladenstein R, Hartmann W, Bauer S , Baumhoer D, van den Berg H, Dijkstra PDS, Dürr HR, Gelderblom H, Hardes J, Hjorth L, Kreyer J, Kruseova J, Leithner A, Scobioala S, Streitbürger A, Tunn PU, Wardelmann E, Windhager R, Jürgens H, Dirksen U; GPOH-Euro-EWING99 consortium.	Which Factors Are Associated with Local Control and Survival of Patients with Localized Pelvic Ewing's Sarcoma? A Retrospective Analysis of Data from the Euro-EWING99 Trial.	Clin Orthop Relat Res. 2019 Sep 26 Epub	4,2
2019	Reichardt P, Schlemmer M, Delgado Perez JR, Papai Z, Prausova J, Melichar B, Fumagalli E, Barone C, Bauer S, Pustowka A, Crippa S, Castellana R, Quiring C, Le Cesne A.	Safety of Imatinib Mesylate in a Multicenter Expanded Access Program in Adult Patients with Gastrointestinal Stromal Tumors in the Adjuvant Setting.	Oncol Res Treat. 2019 Sep 24:1-6.	1,5
2019	Cesne AL, Bauer S , Demetri GD, Han G, Dezzani L, Ahmad Q, Blay JY, Judson I, Schöffski P, Aglietta M, Hohenberger P, Gelderblom H.	Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses.	BMC Cancer. 2019 Aug 13;19(1):794.	8,3
2019	Tap WD, Gelderblom H, Palmerini E, Desai J, Bauer S , Blay JY, Alcindor T, Ganjo K, Martin-Broto J, Ryan CW, Thomas DM, Peterfy C, Healey JH, van de Sande M, Gelhorn HL, Shuster DE, Wang Q, Yver A, Hsu HH, Lin PS, Tong-Starksen S, Stacchiotti S, Wagner AJ; ENLIVEN investigators.	Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial.	Lancet. 2019 Aug 10;394(10197):478-487	59,1
2019	Gröschel S, Hübschmann D, Raimondi F, Horak P, Warsow G, Fröhlich M, Klink B, Gieldon L, Hutter B, Kleinheinz K, Bonekamp D, Marschal O, Chudasama P, Mika J, Groth M, Uhrig S, Krämer S, Heining C, Heilig CE, Richter D, Reisinger E, Pfütze K, Eils R, Wolf S, von Kalle C, Brandts C, Scholl C, Weichert W, Richter S, Bauer S , Penzel R, Schröck E, Stenzinger A, Schlenk RF, Brors B, Russell RB, Glimm H, Schlesner M, Fröhling S	Defective homologous recombination DNA repair as therapeutic target in advanced chordoma.	Nat Commun. 2019 Apr 9;10(1):1635	11,8
2019	Blay JY, Schöffski P, Bauer S , Krarup-Hansen A, Benson C, D'Adamo DR, Jia Y, Maki RG.	Eribulin versus dacarbazine in patients with leiomyosarcoma:	Br J Cancer. 2019 May;120(11):1026-1032	5,4

		subgroup analysis from a phase 3, open-label, randomised study.		
2019	Heinrich MC, Patterson J, Beadling C, Wang Y, Debiec-Rychter M, Dewaele B, Corless CL, Duensing A, Raut CP, Rubin B, Ordog T, van de Rijn M, Call J, Mühlenberg T, Fletcher JA, Bauer S .	Genomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors (GISTs).	Clin Sarcoma Res. 2019 Mar;5:9:3	2,8
2019	Serrano C, Mariño-Enríquez A, Tao DL, Ketzer J, Eilers G, Zhu M, Yu C, Mannan AM, Rubin BP, Demetri GD, Raut CP, Presnall A, McKinley A, Heinrich MC, Czaplinski JT, Sicinska E, Bauer S , George S, Fletcher JA	Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours.	Br J Cancer. 2019 Mar;120(6):612-620	5,4
2019	Schöffski P, Wozniak A, Stacchiotti S, Rutkowski P, Blay JY, Lindner LH, Strauss SJ, Anthoney A, Duffaud F, Richter S, Grünwald V, Leahy MG, Reichardt P, Sufliarsky J, van der Graaf WT, Sciot R, Debiec-Rychter M, van Cann T, Marréaud S, Lia M, Raveloarivahy T, Collette L, Bauer S .	Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'	Ann Oncol. 2019 Feb 1;30(2):344	14,2
2019	Scheer M, Vokuhl C, Blank B, Hallmen E, von Kalle T, Münter M, Wessalowski R, Hartwig M, Sparber-Sauer M, Schlegel PG, Kramm CM, Kontny U, Spriewald B, Kegel T, Bauer S , Kazanowska B, Niggli F, Ladenstein R, Ljungman G, Jahnukainen K, Fuchs J, Bielack SS, Klingebiel T, Koscielniak E; Cooperative Weichteilsarkom Studiengruppe [CWS].	Desmoplastic small round cell tumors: Multimodality treatment and new risk factors.	Cancer Med. 2019 Feb;8(2):527-542	3,4
2019	Keilholz U, Mehnert JM, Bauer S , Bourgeois H, Patel MR, Gravenor D, Nemunaitis JJ, Taylor MH, Wyrwicz L, Lee KW, Kasturi V, Chin K, von Heydebreck A, Gulley JL.	Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial.	J Immunother Cancer. 2019 Jan 16;7(1):12	8,3
2018	Agaimy A, Mueller SK, Harrer T, Bauer S , Thompson LDR	Head and Neck Kaposi Sarcoma: Clinicopathological Analysis of 11 Cases.	Head Neck Pathol. 2018 Dec;12(4):511-516	2,2
2018	Lier, A, Penzel R, Heining C, Horak P, Fröhlich M, Uhrig S, Budczies J, Kirchner M, Volckmar A, Hutter B, Kreutzfeld S, Endris V, Richter D, Wolf S, Pfütze K, Neumann O, Buchhalter I, Morais de Oliveira C, Singer S, Leichsenring J, Herpel E, Klauschen F, Jost P, Metzeler K, Schulze-Osthoff K, Kopp HG, Kindler T, Rieke DT, Lamping M, Brandts C, Falkenhorst J, Bauer S , Schröck E, Folprecht G, Boerries M, von Bubnoff N, Weichert W, Brors B, Lichter P, von Kalle C, Schirrmacher P, Glimm H, Fröhling S, Stenzinger	Validating Comprehensive Next-Generation Sequencing Results for Precision Oncology: The NCT/DKTK Molecularly Aided Stratification for Tumor Eradication Research Experience	JCO Precision Oncology 2018 :2, 1-13	-
2018	Le Tourneau C, Hoimes C, Zarwan C, Wong DJ, Bauer S , Claus R, Wermke M, Hariharan S, von Heydebreck A, Kasturi V, Chand V, Gulley J	Avelumab in Patients With Previously Treated Metastatic Adrenocortical Carcinoma	J Immunother Cancer. 2018 Oct 22;6(1):111	8,3
2018	Whelan J, Le Deley MC, Dirksen U, Le Teuff G, Brennan B, Gaspar N, Hawkins DS, Amller S, Bauer S , Bielack S, Blay JY, Burdach S, Castex MP, Diloo D, Eggert A, Gelderblom H, Gentet JC, Hartmann W, Hassenpflug WA, Hjorth L, Jimenez M, Klingebiel T, Kontny U, Kruseova J, Ladenstein R, Laurence V, Lervat C, Marec-Berard P, Marreaud S, Michon J, Morland B, Paulussen M, Ranft A, Reichardt P, van den Berg H,	High dose chemotherapy with busulfan-melphalan and blood autologous stem cell rescue compared to standard chemotherapy in localized high-risk Ewing sarcoma: Results of R2Loc randomization in Euro-E.W.I.N.G.99 and Ewing2008 controlled trials	J Clin Oncol. 2018 Sep 6	20,9

	Wheatley K, Judson I, Lewis I, Craft A, Juergens H, Oberlin O			
2018	Heinemann M, Ranft A, Langer T, Jürgens H, Kreyer J, Vieth V, Schäfers M, Weckesser M, Simon T, Hassenpflug W, Corbacioglu S, Bielack S, Mayer-Steinacker R, Kühne T, van den Berg H, Gelderblom H, Bauer S , Stegger L, Dirksen U	Recurrence of Ewing sarcoma: Is detection by imaging follow-up protocol associated with survival advantage?	Pediatr Blood Cancer. 2018 Aug 7:e27384	2,4
2018	Yun S, Kim WK, Kwon Y, Jang M, Bauer S , Kim H	Survivin Is a Novel Transcription Regulator of KIT and Is Downregulated by miRNA-494 in Gastrointestinal Stromal Tumors.	Int J Cancer. 2018 May 15;142(10):2080-2093	6,5
2018	Schöffski P, Wozniak A, Kasper B, Aamdal S, Leahy MG, Rutkowski P, Bauer S , Gelderblom H, Italiano A, Lindner LH, Hennig I, Strauss S, Zakotnik B, Anthoney A, Albiges L, Blay JY, Reichardt P, Sufliarsky J, van der Graaf WTA, Debiec-Rychter M, Sciot R, Van Cann T, Marréaud S, Raveloarivahy T, Collette S, Stacchiotti S.	Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3. European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 "CREATE".	Ann Oncol. 2018 Mar 1;29(3):758-765	11,9
2018	Schöffski P, Wozniak A, Leahy MG, Aamdal S, Rutkowski P, Bauer S , Richter S, Grünwald V, Debiec-Rychter M, Sciot R, Geoerger B, Marréaud S, Collette S, Nzokirantevye A, Strauss SJ.	The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 'CREATE'.	Eur J Cancer. 2018 May;94:156-167	4,8
2018	Rothermundt C, Fischer GF, Bauer S , Blay JY, Grünwald V, Italiano A, Kasper B, Kollár A, Lindner LH, Miah A, Sleijfer S, Stacchiotti S, Putora PM.	Pre- and Postoperative Chemotherapy in Localized Extremity Soft Tissue Sarcoma: A European Organization for Research and Treatment of Cancer Expert Survey.	Oncologist. 2018 Apr;23(4):461-467	5,3
2018	Montemurro M, Cioffi A, Domont J, Rutkowski P, Roth AD, von Moos R, Inauen R, Toulmonde M, Burkhard RO, Knuesli C, Bauer S , Cassier P, Schwab H, Le Cesne A, Koeberle D, Baertschi D, Dietrich D, Biaggi C, Prior J, Leyvraz S	Long-term outcome of dasatinib first-line treatment in GIST: A multicenter two-stage phase II trial SAKK 56/07	Cancer. 2018 Apr 1;124(7):1449-1454	6,1
2018	Freudenberg LS, Gauler T, Görges R, Bauer S , Stergar H, Antoch G, Bockisch A, Schütte J.	Somatostatin receptor scintigraphy in advanced renal cell carcinoma. Results of a phase II-trial of somatostatin analogue therapy in patients with advanced RCC	Nuklarmedizin 2018 Jan	1,3
2018	Chudasama P, Sanders MA, Mughal SS, Chung I, Wong SH, Huebschmann D, Rabe S, Hlevnjak M, Zapatka M, Ernst A, Sieverling L, Hutter B, Klink B, Schröck E, Kasper B, Heilig C, Egerer G, Wolf S, von Kalle C, Stenzinger A, Weichert W, Glimm H, Gröschel S, Kopp HG; Omlo G, Lehner, Bauer S , Schimmack S, Ulrich A, Mechtersheimer G, Rippe K, Brors B, Renner M, Hohenberger P, Scholl C, Fröhling S	Integrative genomic and transcriptomic analysis of adult leiomyosarcoma	Nat Commun. 2018 Jan 10;9(1):144	12,1
2017	Montemurro M, Cioffi A, Domont J, Rutkowski P, Roth AD, von Moos R, Inauen R, Toulmonde M, Burkhard RO, Knuesli C, Bauer S, Cassier P, Schwab H, Le Cesne A, Koeberle D, Baertschi D, Dietrich D, Biaggi C, Prior J, Leyvraz S	Long-term outcome of dasatinib first-line treatment in GIST: A multicenter two-stage phase II trial SAKK 56/07	Cancer. 2018 Apr 1;124(7):1449-1454	6,1

2017	Yun S, Kim WK, Kwon Y, Jang M, Bauer S , Kim H	Survivin Is a Novel Transcription Regulator of KIT and Is Downregulated by miRNA-494 in Gastrointestinal Stromal Tumors.	Int J Cancer. 2017 Dec 26	6,5
2017	Kaitsiotou H, Keul M, Hardick J, Mühlenberg T, Ketzer J, Ehrt C, Krüll J, Medda F, Koch O, Giordanetto F, Bauer S , Rauh D	Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT.	J Med Chem. 2017 Nov 9;60(21):8801-8815	6,3
2017	Frank JA, Ranft A, Paulussen M, Juergens H, Kruseova J, Bauer S , Niggli F, Reichardt P, Dirksen U	Results for patients with sarcoma not otherwise specified and other diagnoses than Ewing sarcoma treated according to the Euro-EWING 99 trial.	Pediatr Blood Cancer. 2017 Oct;64(10)	2,5
2017	Podleska LE, Kaya N, Farzaliyev F, Pöttgen C, Bauer S , Taeger G	Lower limb function and quality of life after ILP for soft-tissue sarcoma.	World J Surg Oncol. 2017 Apr 13;15(1):84	1,8
2017	Rothermund C, Pestel GF, Bauer S , Blay JY, Grünwald V, Italiano A, Judson I, Kasper B, Kollar A, Lindner L, Miah A, Schöffski P, Sleijfer S, Stacchiotti S, Putora PM	Pre- and Postoperative Chemotherapy in Localized Extremity Soft Tissue Sarcoma – an Expert Survey	Oncologist	4,8
2017	Gafencu DA, Welter S, Cheufou DH, Ploenes T, Stamatis G, Stuschke M, Theegarten D, Taube C, Bauer S , Aigner C.	Pulmonary metastasectomy for sarcoma-Essen experience.	J Thorac Dis. 2017 Oct;9(Suppl 12):S1278-S1281	2,4
2017	Winer ES, Safran H, Karaszewska B, Bauer S , Khan D, Doerfel S, Burgess P, Kalambakas S, Mostafa Kamel Y, Forget F.	Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study.	Int J Hematol. 2017 Dec;106(6):765-776	1,8
2017	Schöffski P, Wozniak A, Escudier B, Rutkowski P, Anthoney A, Bauer S , Sufliarsky J, van Herpen C, Lindner LH, Grünwald V, Zakotnik B, Lerut E, Debiec-Rychter M, Marréaud S, Lia M, Raveloorivahy T, Collette S, Albiges L.	Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.	Eur J Cancer. 2017 Nov 14;87:147-163	4,8
2017	Tomassi S, Lategahn J, Engel J, Keul M, Tumbrink HL, Ketzer J, Mühlenberg T, Baumann M, Schultz-Fademrecht C, Bauer S , Rauh D.	Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor.	J Med Chem. 2017 Mar 23;60(6):2361-2372	6,3
2017	Wagner AJ, Kindler H, Gelderblom H, Schöffski P, Bauer S , Hohenberger P, Kopp HG, Lopez-Martin JA, Peeters M, Reichardt P, Qin A, Nippgen J, Ilaria RL, Rutkowski P.	A phase II study of a human anti-PDGFR α monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors.	Ann Oncol. 2017 Mar 1;28(3):541-546	11,9
2017	Joensuu H, Wardemann E, Sihto H, Eriksson M, Sundby Hall K, Reichardt A, Hartmann JT, Pink D, Cameron S, Hohenberger P, Al-Batran SE, Schlemmer M, Bauer S , Nilsson B, Kallio R, Junnila J, Vehtari A, Reichardt P.	Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.	JAMA Oncol. 2017 May 1;3(5):602-609	16,6
2017	Schaefer IM, Wang Y, Liang CW, Bahri N, Quattrone A, Doyle L, Mariño-Enríquez A, Lauria A, Zhu M, Debiec-Rychter M, Grunewald S, Hechtman JF, Dufresne A, Antonescu CR, Beadling C, Sicinska ET, van de Rijn M, Demetri GD, Ladanyi M, Corless CL, Heinrich MC, Raut CP, Bauer S , Fletcher JA.	MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation.	Nat Commun. 2017 Mar 8;8:14674	12,1
2017	Joensuu H, Blay JY, Comandone A, Martin-Broto J, Fumagalli E, Grignani G, Del Muro XG, Adenis A, Valverde C, Pousa AL, Bouché O, Italiano A, Bauer	Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib.	Br J Cancer. 2017 Oct 24;117(9):1278-1285	6,0

	S , Barone C, Weiss C, Crippa S, Camozzi M, Castellana R, Le Cesne A.			
2017	Erfanian Y, Grueneisen J, Kirchner J, Wetter A, Podleska LE, Bauer S , Poepel T, Forsting M, Herrmann K, Umutlu L.	Integrated 18F-FDG PET/MRI compared to MRI alone for identification of local recurrences of soft tissue sarcomas: a comparison trial.	Eur J Nucl Med Mol Imaging. 2017 May 31	7,2
2017	Kasper B, Gruenwald V, Reichardt P, Bauer S , Rauch G, Limprecht R, Sommer M, Dimitrakopoulou-Strauss A, Pilz L, Haller F, Hohenberger P.	Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG).	Eur J Cancer. 2017 May;76:60-67	4,8
2017	Podleska LE, Schwindenhammer B, Grabellus F, Bauer S , Steinau HU, Taeger G.	Isolated limb perfusion for liposarcoma : Histopathological response and subgroup analysis after TNF melphalan-based ILP	Chirurg. 2017 May;88(5):429-436	0,6
2016	Engel J, Becker C, Lategahn J, Keul M, Ketzer J, Mühlenberg T, Kollipara L, Schultz-Fademrecht C, Zahedi RP, Bauer S , Rauh D	Insight into the Inhibition of Drug-Resistant Mutants of the Receptor Tyrosine Kinase EGFR	Angew Chem Int Ed Engl. 2016 Aug 26;55(36):10909-12	11,7
2016	Joensuu H, Eriksson M, Sundby Hall K, Reichardt A, Hartmann JT, Pink D, Ramadori G, Hohenberger P, Al-Batran SE, Schlemmer M, Bauer S , Wardelmann E, Nilsson B, Sihto H, Bono P, Kallio R, Junnila J, Alvegård T, Reichardt P.	Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial.	J Clin Oncol. 2016 Jan 20;34(3):244-50.	20,9
2016	Angelika Ihle M, Merkelbach-Bruse S, Hartmann W, Bauer S , Ratner N, Sonobe H, Nishio J, Larsson O, Åman P, Pedeutour F, Taguchi T, Wardelmann E, Buettner R, Schildhaus HU	HR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostat.	Journal of Pathology - Clinical Research 2016 Feb 5;2(2):59-71	5,3
2016	Falkenhorst J, Grunewald S, Mühlenberg T, Marino-Enriquez A, Reis AC, Corless C, Heinrich M, Treckmann J, Podleska LE, Schuler M, Fletcher JA, Bauer S	Inhibitor of Apoptosis Proteins (IAPs) are commonly dysregulated in GIST and can be pharmacologically targeted to enhance the pro-apoptotic activity of imatinib.	Oncotarget. 2016 May 4. doi: 10.18632/oncotarget.9159	6,3
2016	Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, Grignani G, Camargo V, Bauer S , Rha SY, Blay JY, Hohenberger P, D'Adamo D, Guo M, Chmielowski B, Le Cesne A, Demetri GD, Patel SR	Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.	Lancet. 2016 Apr 16;387(10028):1629-37	39
2016	Joensuu H, Eriksson M, Sundby Hall K, Reichardt A, Hartmann JT, Pink D, Ramadori G, Hohenberger P, Al-Batran SE, Schlemmer M, Bauer S , Wardelmann E, Nilsson B, Sihto H, Bono P, Kallio R, Junnila J, Alvegård T, Reichardt P.	Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial.	J Clin Oncol. 2016 Jan 20;34(3):244-50.	20,9
2016	Kinsella P, Greene LM, Bright SA, Pollock JK, Butini S, Campiani G, Bauer S , Williams DC, Zisterer DM	The novel pyrrolo-1,5-benzoxazepine, PBOX-15, synergistically enhances the apoptotic efficacy of imatinib in gastrointestinal stromal tumours; suggested mechanism of action of PBOX-15.	Invest New Drugs. 2016 Apr;34(2):159-67	3,2
2016	Eriksson M, Reichardt P, Sundby Hall K, Schütte J, Cameron S, Hohenberger P, Bauer S , Leinonen M, Reichardt A, Rejmyr Davis M, Alvegård T, Joensuu H	Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour - Does it increase the risk for tumour cell seeding and recurrence?	Eur J Cancer. 2016 May;59:128-33	4,8
2016	Kim WK, Yun S, Park CK, Bauer S , Kim J, Lee MG, Kim H	Sustained mutant KIT activation in the Golgi complex is mediated	Clin Cancer Res. 2016 Jul 20	8,7

		by PKC-θ in gastrointestinal stromal tumors.		
2016	Engel J, Becker C, Lategahn J, Keul M, Ketzer J, Mühlenberg T, Kollipara L, Schultz-Fademrecht C, Zahedi RP, Bauer S , Rauh D	Insight into the Inhibition of Drug-Resistant Mutants of the Receptor Tyrosine Kinase EGFR	Angew Chem Int Ed Engl. 2016 Aug 26;55(36):10909-12	11,7
2015	Ihle MA, Trautmann M, Kuenstlinger H, Huss S, Heydt C, Fassunke J, Wardelmann E, Bauer S , Schildhaus HU, Buettner R, Merkelbach-Bruse S	miRNA-221 and miRNA-222 induce apoptosis via the KIT/AKT signalling pathway in gastrointestinal stromal tumours	Molecular Oncology 2015, in press	5,8
2015	Mühlenberg T, Grunewald S, Treckmann J, Podleska L, Schuler M, Fletcher JA, Bauer S	Inhibition of KIT-Glycosylation by 2-Deoxyglucose Abrogates KIT-Signaling and Combination with ABT-263 Synergistically Induces Apoptosis in Gastrointestinal Stromal Tumor	PLOSone DOI:10.1371/journal.pone.0120531	3,2
2014	Garner AP, Gozgit JM, Anjum R, Vodala S, Schrock A, Zhou T, Serrano C, Eilers G, Zhu M, Ketzer J, Wardwell S, Ning Y, Song Y, Kohlmann A, Wang F, Clarkson T, Heinrich MC, Fletcher JA, Bauer S , Rivera VM	Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients.	Clin Cancer Res 2014 20(22): 5745-55	8,2
2014	Joensuu H, Eriksson M, Hall KS, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S , Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Ballman KV, Leinonen M, DeMatteo RP, Reichardt P.	Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib.	Cancer. 2014 Aug 1;120(15):2325-33	4,9
2014	Kasper B, Sleijfer S, Litière S, Marreaud S, Verweij J, Hodge RA, Bauer S , Kerst JM, van der Graaf WT	Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072.	Ann Oncol. 2014 Mar;25(3):719-24	7,4
2014	Bauer S , Rutkowski P, Hohenberger P, Miceli R, Fumagalli E, Siedlecki JA, Nguyen BP, Kerst M, Fiore M, Nyckowski P, Hoiczyk M, Cats A, Casali PG, Treckmann J, van Coevorden F, Gronchi A	Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib – Analysis of prognostic factors (EORTC-STBSG collaborative study).	European Journal of Surgical Oncology 2014 Apr;40(4):412-9	2,6
2014	Gelderblom H, Blay JY, Seddon BM, Leahy M, Ray-Coquard I, Sleijfer S, Kerst JM, Rutkowski P, Bauer S , Ouali M, Marreaud S, van der Straaten RJ, Guchelaar HJ, Weitman SD, Hogendoorn PC, Hohenberger P	Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group 15andomized phase II and pharmacogenetic study.	Eur J Cancer. 2014 Jan;50(2):388-96	5,3
2013	Schwindenhammer B, Podleska LE, Kutritz A, Bauer S , Sheu SY, Taeger G, Kurt Werner S, Grabelius F.	The pathologic response of resected synovial sarcomas to hyperthermic isolated limb perfusion with melphalan and TNF-α: a comparison with the whole group of resected soft tissue sarcomas.	World J Surg Oncol. 2013 Aug 12;11(1):185	1,2
2013	Bauer S , Hilger R-A., Mühlenberg T., Grabelius F., Nagarajah J., Hoiczyk M., Reichardt A., Ahrens M., Reichardt P., Grunewald S., Scheulen M.E., Pustowka A., Bock E., Schuler M., Pink D.	Phase I Study of Panobinostat and Imatinib in Patients with Treatment-Refractory Metastatic Gastrointestinal Stromal Tumors	British Journal of Cancer	5,0

2013	Richters A., Ketzer J., Getlik M., Grutter C., Schneider R., Heuckmann J.M., Heynck S., Sos M.L., Gupta A., Unger A., Schultz-Fademrecht C., Thomas R.K., Bauer S. , Rauh D.	Targeting Gain of Function and Resistance Mutations in Abl and KIT by Hybrid Compound Design	J.Med.Chem. epub ahead of print	5,61
2013	Simon S., Grabellus F., Ferrera L., Galietta L.J., Schwindenhammer B., Mühlenberg T., Taeger G., Eilers G., Treckmann J., Breitenbuecher F., Schuler M., Taguchi T., Fletcher J.A., Bauer S.	DOG1 regulates growth and IGFBP5 in gastrointestinal stromal	Cancer Research 73 (12) 3661-3670	8,65
2013	Hoiczyk M., Grabellus F., Podleska L., Ahrens M., Schwindenhammer B., Taeger G., Pöttgen C., Schuler M., Bauer S.	Trabectedin in metastatic soft tissue sarcomas – role of pretreatment and age	International Journal of Oncology 43(1) 23-8	2,39
2013	Demetri G.D., Reichardt P., Kang Y.-K., Blay J.-Y., Rutkowski P., Gelderblom H., Hohenberger P., Leahy M., von Mehren M., Joensuu H., Badalamenti G., Blackstein M., Le Cesne A., Schoffski P., Maki R.G., Bauer S. , Nguyen B.B., Xu J., Nishida T., Chung J., Kappeler C., Kuss I., Laurent D., Casali P.G.	Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial	The Lancet 381(9863) 295-302	38,3
2013	Montemurro M., Gelderblom H., Bitz U., Schutte J., Blay J.Y., Joensuu H., Trent J., Bauer S. , Rutkowski P., Duffaud F., Pink D.	Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis	European Journal of Cancer 49(5) 1027-31	5,5
2013	Grabellus F., Podleska L.E., Sheu S.-Y., Bauer S. , Pottgen C., Kloeters C., Hoiczyk M., Lauenstein T.C., Schmid K.W., Taeger G.	Neoadjuvant treatment improves capsular integrity and the width of the fibrous capsule of high-grade soft-tissue sarcomas	European Journal of Surgical Oncology 39(1) 61-7	2,5
2012	Welter S., Grabellus F., Bauer S. , Schuler M., Eberhardt W., Totsch M., Stamatis G.	Growth patterns of lung metastases from sarcoma: Prognostic and surgical implications from histology	Interactive Cardiovascular and Thoracic Surgery , 15(4) 612-17	1,0
2012	Hartmann J.T., Bauer S. , Egerer G., Horger M.S., Kopp H.-G., Grunwald V., Mayer F.	Pemetrexed in patients with refractory soft tissue sarcoma: A non-comparative multicenter phase II study of the German Sarcoma Group AIO-STS 005	Investigational New Drugs 1-8	3,4
2012	Henze J., Mühlenberg T., Simon S., Grabellus F., Rubin B., Taeger G., Schuler M., Treckmann J., Debiec-Rychter M., Taguchi T., Fletcher J.A., Bauer S.	P53 modulation as a therapeutic strategy in gastrointestinal stromal tumors	PLoS ONE 7(5)	4,1
2012	Joensuu H., Eriksson M., Hall K.S., Hartmann J.T., Pink D., Schutte J., Ramadori G., Hohenberger P., Duyster J., Al-Batran S.-E., Schlemmer M., Bauer S. , Wardelmann E., Sarlomo-Rikala M., Nilsson B., Sihto H., Monge O.R., Bono P., Kallio R., Vehtari A., Leinonen M., Alvegard T., Reichardt P.	One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: A randomized trial	JAMA - Journal of the American Medical Association 307(12), 1265-72	30,0
2011	Hahn S., Bauer S. , Heusner T.A., Ebeling P., Hamami M.E., Stahl A., Forsting M., Bockisch A., Antoch G.	Postoperative FDG-PET/CT staging in GIST: Is there a benefit following R0 resection?	European Journal of Radiology 80(3), 670-4	2,6
2011	Schoffski P., Ray-Coquard I.L., Cioffi A., Bui N.B., Bauer S. , Hartmann J.T., Krarup-Hansen A., Grunwald V., Sciot R., Dumez H., Blay J.-Y., Le Cesne A., Wanders J., Hayward C., Marreaud S., Ouali M., Hohenberger P.	Activity of eribulin mesylate in patients with soft-tissue sarcoma: A phase 2 study in four independent histological subtypes	The Lancet Oncology 12(11), 1045-52	22,6

2011	Welter S., Grabellus F., Bauer S. , Schmid K.W., Stamatis G., Totsch M.	Growth patterns of lung metastases from sarcomas	Virchows Archiv 459(2), 213-19	2,5
2011	Schlemmer M., Bauer S. , Schutte R., Hartmann J.T., Bokemeyer C., Hosius C., Reichardt P.	Activity and side effects of imatinib in patients with gastrointestinal stromal tumors: Data from a german multicenter trial	European Journal of Medical Research 16(5), 206-12	1,0
2011	Grabellus F., Kraft C., Sheu-Grabellus S.-Y.I., Bauer S. , Podleska L.E., Lauenstein T.C., Pottgen C., Konik M.J., Schmid K.W., Taeger G.	Tumor vascularization and histopathologic regression of soft tissue sarcomas treated with isolated limb perfusion with TNF- $\hat{\pm}$ and melphalan	Journal of Surgical Oncology 103(5), 371-79	2,1
2010	Grabellus F., Konik M.J., Worm K., Sheu S.-Y., Van De Nes J.A.P., Bauer S. , Paulus W., Egensperger R., Schmid K.W.	MET overexpressing chordomas frequently exhibit polysomy of chromosome 7 but no MET activation through sarcoma-specific gene fusions	Tumor Biology 31(3), 157-63	2,0
2010	Schutt P., Schutt B., Switala M., Bauer S., Stamatis G., Opalka B., Eberhardt W., Schuler M., Horn P.A., Rebmann V.	Prognostic relevance of soluble human leukocyte antigen-G and total human leukocyte antigen class I molecules in lung cancer patients	Human Immunology 71(5), 489-95	2,9
2010	Bauer S. , Mühlenberg T., Leahy M., Hoiczyk M., Gauler T., Schuler M., Looijenga L.	Therapeutic Potential of Mdm2 Inhibition in Malignant Germ Cell Tumours	European Urology 57(4), 679-87	8,8
2010	Bauer S. , Parry JA, Mühlenberg T, Brown MF, Seneviratne D, Chatterjee P, Chin A, Rubin BP, Kuan SF, Fletcher JA, Duensing S, Duensing A.	Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells	Cancer Research 70(1), 150-59	8,2
2009	Mühlenberg T., Zhang Y., Wagner A.J., Grabellus F., Bradner J., Taeger G., Lang H., Taguchi T., Schuler M., Fletcher J.A., Bauer S.	Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors	Cancer Research 69(17), 6941-50	7,5
2007	Reichardt P., Nielsen O.S., Bauer S. , Hartmann J.T., Schoffski P., Christensen T.B., Pink D., Daugaard S., Marreaud S., Van Glabbeke M., Blay J.Y.	Exatecan in pretreated adult patients with advanced soft tissue sarcoma: Results of a phase II - Study of the EORTC Soft Tissue and Bone Sarcoma Group	European Journal of Cancer 43(6), 1017-22	4,5
2006	Bauer S. , Yu L.K., Demetri G.D., Fletcher J.A.	Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor	Cancer Research 66(18), 9153-61	7,7
2005	Bauer S. , Hartmann J.T., De Wit M., Lang H., Grabellus F., Antoch G., Niebel W., Erhard J., Ebeling P., Zeth M., Taeger G., Seeber S., Flasshove M., Schutte J.	Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib	International Journal of Cancer 117(2), 316-25	4,7
2005	Bauer S. , Maier S.K.G., Neyses L., Maass A.H.	Optimization of gene transfer into neonatal rat cardiomyocytes and unmasking of cytomegalovirus promoter silencing	DNA and Cell Biology 24(6), 381-387	1,8
2004	Antoch G., Kanja J., Bauer S. , Kuehl H., Renzing-Koehler K., Schuette J., Bockisch A., Debatin J.F., Freudenberg L.S.	Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (ST1571) therapy in patients with gastrointestinal stromal tumors	Journal of Nuclear Medicine 45(3), 357-365	5,4
2003	Hilger R.A., Diaz-Carballo D., Bauer S. , Kredtke S., Scheulen M.E., Seeber S., Strumberg D.	Circadian rhythm in the regulation of the MAP kinase pathway--pitfall in the determination of surrogate parameters?	International journal of clinical pharmacology and therapeutics 41(12), 614-15	0,9
2003	Maass A., Langer S.J., Oberdorf-Maass S., Bauer S., Neyses L., Leinwand L.A.	Rational promoter selection for gene transfer into cardiac cells	Journal of Molecular and Cellular Cardiology 35(7), 823-31	5,0

2002	Bauer S. , Hartung J., Gauler T., Gocke P., Trarbach T., Flasshove M., Nowrouzian M.R., Bojko P., Hense J., Seeber S., Schutte J.	Gemcitabine-containing chemotherapy in the treatment of patients with advanced soft tissue sarcoma [Gemcitabinhaltige Chemotherapie in der Behandlung von Patienten mit fortgeschrittenen Weichteilsarkomen]	Tumor Diagnostik und Therapie 23(6), 219-24	0,2
------	--	---	---	-----

CASE reports

2018	Hamacher R, Kämpfe D, Reuter-Jessen K, Pöttgen C, Podleska LE, Farzaliyev F, Steinau HU, Schuler M, Schildhaus HU, Bauer S	Dramatic response to pembrolizumab of a PD-L1-positive, advanced angiosarcoma of the scalp	Journal of Clinical Oncology – Precision Oncology, in Press	-
2014	Kordelas L, Bauer S , Schuler M, Beelen DW, Gauler TC	Successful resuscitation of a patient with ventricular fibrillation due to hypomagnesemia under cetuximab therapy	Tumordiagn u Ther 2014; 35: 25-27	-
2012	Hoiczyk M, Ildiodromitis K, Bauer S , Konorza T, Philipp S, Bankfalvi A, Gerl JM, Schuler M, Erbel R	Intimal sarcoma of the pulmonary artery with unusual findings: a case report	Clin Res Cardiol 2012 101(5): 397-401	4,5
2010	Grabellus F., Sheu S.-Y., Bauer S. , Speich N., Schmid K.W., Worm K.	A novel primary KIT exon 9 single nucleotide substitution c.1427G>T (p.Ser476Ile) in a gastrointestinal stromal tumor	Virchows Archiv 457(5), 623-25	2,3
2002	Bauer S. , Hagen V., Pielken H.J., Bojko P., Seeber S., Schutte J.	Imatinib mesylate therapy in patients with gastrointestinal stromal tumors and impaired liver function	Anti-Cancer Drugs 13(8), 847-49	2,2

REVIEWS

2019	Falkenhorst J, Hamacher R, Bauer S.	New therapeutic agents in gastrointestinal stromal tumours.	Curr Opin Oncol. 2019 Jul;31(4):322-328	3,3
2019	Ugurel S, Kortmann RD, Mohr P, Mentzel T, Garbe C, Breuninger H, Bauer S , Grabbe S.	S1 guidelines for dermatofibrosarcoma protuberans (DFSP) – update 2018.	J Dtsch Dermatol Ges. 2019 Jun;17(6):663-668	3,9
2019	Bauer S, Dirksen U, Schildhaus HU.	[Systemic therapy of sarcomas : New biomarkers and therapeutic strategies].	Pathologe. 2019 Jul;40(4):436-442	0,5
2019	Hamacher R, Falkenhorst J, Treckmann J, Bauer S	[Imatinib and beyond-what is important for surgery?]	Chirurg. 2019 Mar 21	0,7
2018	Hemming ML, Heinrich MC, Bauer S, George S.	Translational Insights into Gastrointestinal Stromal Tumor and Current Clinical Advances.	Ann Oncol. 2018 Aug 8	13,9
2018	Casali PG, Abecassis N, Bauer S, ..., Blay JY	Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.	Ann Oncol. 2018 Oct 1;29(Supplement_4):iv68-iv78	11,9
2018	Casali PG, Abecassis N, Bauer S, ..., Blay JY	Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical	Ann Oncol. 2018 Oct	11,9

		Practice Guidelines for diagnosis, treatment and follow-up.	1:29(Supplement_4):iv51-iv67	
2018	Casali PG, Bielack S, Abecassis N, Aro HT, Bauer S, ..., Blay JY	Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.	Ann Oncol. 2018 Oct 1:29(Supplement_4):iv79-iv95	11,9
2018	Bornfeld N, Biewald E, Bauer S , Temming P, Lohmann D, Zeschnigk M	The Interdisciplinary Diagnosis and Treatment of Intraocular Tumors.	Dtsch Arztebl Int. 2018 Feb 16;115(7):106-111	4,3
2018	Ray-Coquard I, Serre D, Reichardt P, Martín-Broto J, Bauer S	Options for treating different soft tissue sarcoma subtypes.	Future Oncol. 2018 May;14(10s):25-49	2,1
2017	Hamacher R, Bauer S	Preclinical models for translational sarcoma research.	Curr Opin Oncol. 2017 Jul;29(4):275-285	3,4
2016	Pogorzelski M, Falkenhorst J, Bauer S	Molecular subtypes of gastrointestinal stromal tumor requiring specific treatments.	Curr Opin Oncol. 2016 Jul;28(4):331-7	4,6
2016	Daigeler A, Lehnhardt M, Bauer S , Goldhammer S, Vogt PM	Plastic Surgery in Palliative Care - Report on the Consensus Workshop of the 37th Annual Meeting of the German-language Group for Microsurgery of the Peripheral Nerves and Vessels (DAM) 2016 in Bochum	Handchir Mikrochir Plast Chir. 2016 Dec;48(6):340-345	0,7
2016	Falkenhorst J, Bauer S	Gastrointestinale Stromatumoren	Trillium Krebsmedizin; 2016; 25(2)	
2016	Bauer S	Sarkome – bösartige Weichteiltumoren: Diagnostik und Therapie	Forum Sanitas 3/2016	
2015	Agaimy A, Bauer S , Beham A, Bertolini J, Haller F, Koschny R, Maier J, Montemurro M, Perez D, Schaefer IM, Schildhaus HU, Wurst C, Cameron S	[Gastrointestinal stromal tumours (GIST)--development in pathology, surgery and medical therapy. Developed during the 10th German GIST-meeting, Göttingen].	Z Gastroenterol. 2015 Mar;53(3):235-43	1,1
2013	Henze J, Bauer S.	Liposarcomas	Hematol Oncol Clin North Am. 2013 Oct;27(5):939-55	2,3
2013	Abendroth A., Bauer S.	<i>Adjuvant</i> chemotherapy for soft tissue sarcoma? A clear no – well – yes-ish	Dtsch Med Wochenschr. 2013 Oct;138(41):2107-10	
2012	Bauer S. , Schmidberger H., Trefzer U.	Individualized tumor therapy and status quo in melanoma [Individualisierte Tumortherapie und Status quo beim Melanom]	Onkologie 35 (SUPPL. 2), 2-6	0.9
2011	Montemurro M., Bauer S.	Treatment of gastrointestinal stromal tumor after imatinib and sunitinib	Current Opinion in Oncology 23(4), 367-72	4.1
2012	Debiec-Rychter M, Bauer S	“Other tyrosine kinase inhibitors in clinical trials” from the book: Tyrosine Kinase Inhibitors for Gastrointestinal Stromal Tumors	Future Medicine; September 2012, Pages 40-48	
2012	Bauer S , Montemurro M	“Imatinib” from the book: Tyrosine Kinase Inhibitors for Gastrointestinal Stromal Tumors	Future Medicine; September 2012, Pages 18-29	
2010	Hoiczyk M., Grabellus F., Bauer S.	Gastrointestinal stromal tumors – Epidemiology, etiology and prognosis [Gastrointestinale Stromatumoren Epidemiologie, Ätiologie und Prognose]	Tumor Diagnostik und Therapie 31(5), 255-58	0.01

2009	Heinrich M, George S, Bauer S , Fletcher JA.	Optimizing the Treatment of Gastrointestinal Stromal Tumors: The Roles of Tumor Genotyping, Imatinib Blood-level Testing, and New Therapeutic Strategies.	ASCO Educational Book	
2006	Bauer S , Hartmann JT.	Locally advanced and metastatic sarcoma (adult type) including gastrointestinal stromal tumors.	Crit Rev Oncol Hematol. 2006 Nov;60(2):112-30	5,0
2007	Bauer S. , Lang H.	The challenge of opportunities: How far can and should we go with targeted treatments and modern diagnostics in gastrointestinal stromal tumors?	European Journal of Gastroenterology and Hepatology 19(8), 619-22	2.3
2006	Hartmann J.T., Bauer S.	Soft tissue sarcoma	Update on Cancer Therapeutics 1(3), 385-402	
2004	Bauer S , Seeber S, Schütte J.	Gemcitabine in the treatment of soft tissue sarcomas.	Onkologie. 2004 Apr;27(2):180-6	0,8
2004	Schutte J., Bauer S.	Gastrointestinal stromal tumors (GIST) – Systemic treatment with imatinib and treatment monitoring [Gastrointestinale stromatumoren (GIST) – Medikamentöse Behandlung mit Imatinib und Therapieüberwachung]	Tumor Diagnostik und Therapie 25(4), 174-76	0.08
2002	Bauer S. , Schutte J.	The value of neoadjuvant therapy and adjuvant chemotherapy in the treatment of soft tissue sarcomas [Stellenwert neoadjuvanter Therapieverfahren und adjuvanter Chemotherapie in der Behandlung von Weichgewebssarkomen]	Onkologe 8(4), 334-341	0.3
2002	Opalka B., Bauer S. , Schutte J.	Lung tumors [Lungentumoren]	Medizinische Genetik 14(2), 139-44	0.5
2004	Bauer S , Seeber S, Schütte J.	Gemcitabine in the treatment of soft tissue sarcomas.	Onkologie. 2004 Apr;27(2):180-6	0,8